STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)

NCT07278310 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1025

Last updated 2026-04-09

No results posted yet for this study

Summary

To evaluate the safety and efficacy of Siegel™ TAVR System in the treatment of subjects with symptomatic severe native aortic stenosis.

Conditions

  • Symptomatic Severe Native Aortic Stenosis
  • Aortic Stenosis

Interventions

DEVICE

TAVR Device

Commercially available TAVR Device

DEVICE

Siegel TAVR Device

Siegel TAVR Device

Sponsors & Collaborators

  • MiRus

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2028-04-30
Completion
2028-04-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07278310 on ClinicalTrials.gov